Protein kinase C - possible therapeutic target to treat cardiovascular diseases

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 10, Issue 4, 2010, Pages 292-308

  Bynagari Settipalli, Yamini S ^a   Chari, Ramya ^a   Kilpatrick, Laurie ^a,c   Kunapuli, Satya P ^a,b,c  

^a TEMPLE UNIVERSITY   (United States)

^b Department of Pharmacology ^*  (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Cardiovascular diseases; Metabolic Syndrome; Protein kinase C; Stroke; Thrombosis

Indexed keywords

1 HEXYLINDOLACTAM V10; 12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; INDOLACTAM V; PHORBOL 12 MYRISTATE ACITATE; PHORBOL 13 ACETATE 12 MYRISTATE; PHORBOL ESTER DERIVATIVE; PROTEIN KINASE C; PROTEIN KINASE C ACTIVATOR; PROTEIN KINASE C INHIBITOR; STAUROSPORINE; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HEART MUSCLE CELL; HUMAN; ISCHEMIC PRECONDITIONING; MACROPHAGE; METABOLIC SYNDROME X; MONOCYTE; NONHUMAN; PATHOGENESIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN STRUCTURE; REPERFUSION INJURY; SMOOTH MUSCLE FIBER; STROKE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; THROMBOGENESIS; VASCULAR SMOOTH MUSCLE;

EID: 78649928853     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152910793743869     Document Type: Article

References (273)

1. Heron, M.; Hoyert, D.L.; Murphy, S.L.; Xu, J.; Kochanek, K.D.; Tejada-Vera, B. Deaths: final data for 2006. Natl. Vital. Stat. Rep., 2009, 57(14), 1-134.
2. Setacci, C.; de Donato, G.; Setacci, F.; Chisci, E. Diabetic patients: epidemiology and global impact. J. Cardiovasc. Surg. (Torino)., 2009, 50(3), 263-73.
3. Murray, C.J.; Lopez, A.D. Global and regional cause-of-death patterns in 1990. Bull. World Health Organ., 1994, 72(3), 447-80.
4. WHO, Cardio Vascular Diseases. Updated September 2009.
5. Lloyd-Jones, D.; Adams, R.J.; Brown, T.M.; Carnethon, M.; Dai, S.; De Simone, G.; Ferguson, T.B.; Ford, E.; Furie, K.; Gillespie, C.; Go, A.; Greenlund, K.; Haase, N.; Hailpern, S.; Ho, P.M.; Howard, V.; Kissela, B.; Kittner, S.; Lackland, D.; Lisabeth, L.; Marelli, A.; McDermott, M.M.; Meigs, J.; Mozaffarian, D.; Mussolino, M.; Nichol, G.; Roger, V.L.; Rosamond, W.; Sacco, R.; Sorlie, P.; Stafford, R.; Thom, T.; Wasserthiel-Smoller, S.; Wong, N.D.; Wylie-Rosett, J. Heart disease and stroke statistics--2010 update: a report from the american heart association. Circulation, 2010, 121(7), e46-e215.
6. Dekker, L.V.; Parker, P.J. Protein kinase C-a question of specificity. Trends Biochem. Sci., 1994, 19(2), 73-77.
7. Newton, A.C. Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. Biochem. J., 2003, 370(Pt 2), 361-371.
8. Mellor, H.; Parker, P.J. The extended protein kinase C superfamily. Biochem. J., 1998, 332(Pt 2), 281-292.
9. House, C.; Kemp, B.E. Protein kinase C contains a pseudosubstrate prototope in its regulatory domain. Science, 1987, 238(4834), 1726-1728.
10. House, C.; Wettenhall, R.E.; Kemp, B.E. The influence of basic residues on the substrate specificity of protein kinase C. J. Biol. Chem., 1987, 262(2), 772-777.
11. Hurley, J.H.; Newton, A.C.; Parker, P.J.; Blumberg, P.M.; Nishizuka, Y. Taxonomy and function of C1 protein kinase C homology domains. Protein Sci., 1997, 6(2), 477-480.
12. Nakamura, H.; Kishi, Y.; Pajares, M.A.; Rando, R.R. Structural basis of protein kinase C activation by tumor promoters. Proc. Natl. Acad. Sci. USA, 1989, 86(24), 9672-9676.
13. Lorenzo, P.S.; Bogi, K.; Hughes, K.M.; Beheshti, M.; Bhattacharyya, D.; Garfield, S.H.; Pettit, G.R.; Blumberg, P.M. Differential roles of the tandem C1 domains of protein kinase C delta in the biphasic down-regulation induced by bryostatin 1. Cancer Res., 1999, 59(24), 6137-44.
14. Giorgione, J.; Hysell, M.; Harvey, D.F.; Newton, A.C. Contribution of the C1A and C1B domains to the membrane interaction of protein kinase C. Biochemistry, 2003, 42(38), 11194-11202.
15. Luo, J.H.; Weinstein, I.B. Calcium-dependent activation of protein kinase C. The role of the C2 domain in divalent cation selectivity. J. Biol. Chem., 1993, 268(31), 23580-23584.
16. Ron, D.; Mochly-Rosen, D. An autoregulatory region in protein kinase C: the pseudoanchoring site. Proc. Natl. Acad. Sci. USA, 1995, 92(2), 492-496.
17. Parker, P.J.; Murray-Rust, J. PKC at a glance. J. Cell Sci., 2004, 117(Pt 2), 131-132.
18. O'Brian, C.A.; Ward, N.E. Biology of the protein kinase C family. Cancer Metastasis Rev., 1989, 8(3), 199-214.
19. Stabnel, S. Protein kinase C--an enzyme and its relatives. Semin. Cancer Biol., 1994, 5(4), 277-284.
20. Dries, D.R.; Gallegos, L.L.; Newton, A.C. A single residue in the C1 domain sensitizes novel protein kinase C isoforms to cellular diacylglycerol production. J. Biol. Chem., 2007, 282(2), 826-830.
21. Sutton, R.B.; Sprang, S.R. Structure of the protein kinase Cbeta phospholipid-binding C2 domain complexed with Ca2+. Structure, 1998, 6 (11), 1395-1405.
22. Newton, A.C. Protein kinase C: structure, function, and regulation. J. Biol. Chem., 1995, 270(48), 28495-28498.
23. Hirano, Y.; Yoshinaga, S.; Ogura, K.; Yokochi, M.; Noda, Y.; Sumimoto, H.; Inagaki, F. Solution structure of atypical protein kinase C PB1 domain and its mode of interaction with ZIP/p62 and MEK5. J. Biol. Chem., 2004, 279(30), 31883-318890.
24. Nakanishi, H.; Brewer, K.A.; Exton, J.H. Activation of the zeta isozyme of protein kinase C by phosphatidylinositol 3,4,5- trisphosphate. J. Biol. Chem., 1993, 268(1), 13-16.
25. Nakanishi, H.; Exton, J.H. Purification and characterization of the zeta isoform of protein kinase C from bovine kidney. J. Biol. Chem., 1992, 267(23), 16347-16354.
26. Newton, A.C. Regulation of protein kinase C. Curr. Opin. Cell Biol., 1997, 9(2), 161-167.
27. Blobe, G.C.; Obeid, L.M.; Hannun, Y.A. Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Rev., 1994, 13(3-4), 411-431.
28. Newton, A.C.; Johnson, J.E. Protein kinase C: a paradigm for regulation of protein function by two membrane-targeting modules. Biochim. Biophys. Acta., 1998, 1376(2), 155-172.
29. Newton, A.C., Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem. Rev., 2001, 101 (8), 2353-2364.
30. Keranen, L.M.; Dutil, E.M.; Newton, A.C. Protein kinase C is regulated in vivo by three functionally distinct phosphorylations. Curr. Biol., 1995, 5(12), 1394-1403.
31. Behn-Krappa, A.; Newton, A.C. The hydrophobic phosphorylation motif of conventional protein kinase C is regulated by autophosphorylation. Curr. Biol., 1999, 9 (14), 728-737.
32. Dutil, E.M.; Keranen, L.M.; DePaoli-Roach, A.A.; Newton, A.C. In vivo regulation of protein kinase C by trans-phosphorylation followed by autophosphorylation. J. Biol. Chem., 1994, 269(47), 29359-29362.
33. Edwards, A.S.; Newton, A.C. Phosphorylation at conserved carboxyl-terminal hydrophobic motif regulates the catalytic and regulatory domains of protein kinase C. J. Biol. Chem., 1997, 272(29), 18382-18390.
34. Gao, T.; Newton, A.C. Invariant Leu preceding turn motif phosphorylation site controls the interaction of protein kinase C with Hsp70. J. Biol. Chem., 2006, 281(43), 32461-32468.
35. Cameron, A.J.; De Rycker, M.; Calleja, V.; Alcor, D.; Kjaer, S.; Kostelecky, B.; Saurin, A.; Faisal, A.; Laguerre, M.; Hemmings, B.A.; McDonald, N.; Larijani, B.; Parker, P.J. Protein kinases, from B to C. Biochem. Soc. Trans., 2007, 35(Pt 5), 1013-1017.
36. Standaert, M.L.; Bandyopadhyay, G.; Kanoh, Y.; Sajan, M.P.; Farese, R.V. Insulin and PIP3 activate PKC-zeta by mechanisms that are both dependent and independent of phosphorylation of activation loop (T410) and autophosphorylation (T560) sites. Biochemistry, 2001, 40(1), 249-255.
37. Egawa, K.; Maegawa, H.; Shi, K.; Nakamura, T.; Obata, T.; Yoshizaki, T.; Morino, K.; Shimizu, S.; Nishio, Y.; Suzuki, E.; Kashiwagi, A. Membrane localization of 3-phosphoinositide-dependent protein kinase-1 stimulates activities of Akt and atypical protein kinase C but does not stimulate glucose transport and glycogen synthesis in 3T3-L1 adipocytes. J. Biol. Chem., 2002, 277 (41), 38863-38869.
38. Kanoh, Y.; Sajan, M. P.; Bandyopadhyay, G.; Miura, A.; Standaert, M.L.; Farese, R. V. Defective activation of atypical protein kinase C zeta and lambda by insulin and phosphatidylinositol-3,4,5- (PO4)(3) in skeletal muscle of rats following high-fat feeding and streptozotocin-induced diabetes. Endocrinology, 2003, 144 (3), 947-954.
39. Smith, L.; Wang, Z.; Smith, J.B. Caspase processing activates atypical protein kinase C zeta by relieving autoinhibition and destabilizes the protein. Biochem. J., 2003, 375 (Pt 3), 663-671.
40. Frutos, S.; Moscat, J.; Diaz-Meco, M.T. Cleavage of zetaPKC but not lambda/iotaPKC by caspase-3 during UV-induced apoptosis. J. Biol. Chem., 1999, 274(16), 10765-10770.
41. Basu, A.; Lu, D.; Sun, B.; Moor, A.N.; Akkaraju, G.R.; Huang, J. Proteolytic activation of protein kinase C-epsilon by caspasemediated processing and transduction of antiapoptotic signals. J Biol. Chem., 2002, 277(44), 41850-41856.
42. Koriyama, H.; Kouchi, Z.; Umeda, T.; Saido, T.C.; Momoi, T.; Ishiura, S.; Suzuki, K. Proteolytic activation of protein kinase C delta and epsilon by caspase-3 in U937 cells during chemotherapeutic agent-induced apoptosis. Cell Signal, 1999, 11(11), 831-838.
43. England, K.; Rumsby, M. Methods to study dephosphorylation of protein kinase C in vivo. Methods Mol. Biol., 2003, 233, 217-232.
44. Saito, N. Fluorescence imaging of protein kinase C translocation in living cells. Methods Mol. Biol., 2003, 233, 93-103.
45. Lewin, N.E.; Blumberg, P.M. [3H]Phorbol 12,13-dibutyrate binding assay for protein kinase C and related proteins. Methods Mol. Biol., 2003, 233, 129-156.
46. Li, W.; Mischak, H.; Yu, J.C.; Wang, L.M.; Mushinski, J.F.; Heidaran, M.A.; Pierce, J.H. Tyrosine phosphorylation of protein kinase C-delta in response to its activation. J. Biol. Chem., 1994, 269 (4), 2349-2352.
47. Joseloff, E.; Cataisson, C.; Aamodt, H.; Ocheni, H.; Blumberg, P.; Kraker, A.J.; Yuspa, S.H. Src family kinases phosphorylate protein kinase C delta on tyrosine residues and modify the neoplastic phenotype of skin keratinocytes. J. Biol. Chem., 2002, 277 (14), 12318-12323.
48. Konishi, H.; Tanaka, M.; Takemura, Y.; Matsuzaki, H.; Ono, Y.; Kikkawa, U.; Nishizuka, Y. Activation of protein kinase C by tyrosine phosphorylation in response to H2O2. Proc. Natl. Acad. Sci. USA, 1997, 94(21), 11233-11237.
49. Denning, M.F.; Dlugosz, A.A.; Howett, M.K.; Yuspa, S.H. Expression of an oncogenic rasHa gene in murine keratinocytes induces tyrosine phosphorylation and reduced activity of protein kinase C delta. J. Biol. Chem., 1993, 268(35), 26079-26081.
50. Schechtman, D.; Mochly-Rosen, D. Adaptor proteins in protein kinase C-mediated signal transduction. Oncogene, 2001, 20(44), 6339-6347.
51. Souroujon, M.C.; Mochly-Rosen, D. Peptide modulators of proteinprotein interactions in intracellular signaling. Nat. Biotechnol., 1998, 16(10), 919-924.
52. Leitges, M.; Kovac, J.; Plomann, M.; Linden, D. J. A unique PDZ ligand in PKCalpha confers induction of cerebellar long-term synaptic depression. Neuron, 2004, 44(4), 585-594.
53. Colon-Gonzalez, F.; Kazanietz, M.G. C1 domains exposed: from diacylglycerol binding to protein-protein interactions. Biochim. Biophys. Acta., 2006, 1761(8), 827-837.
54. Feng, X.; Zhang, J.; Barak, L.S.; Meyer, T.; Caron, M.G.; Hannun, Y.A. Visualization of dynamic trafficking of a protein kinase C betaII/green fluorescent protein conjugate reveals differences in G protein-coupled receptor activation and desensitization. J. Biol. Chem., 1998, 273(17), 10755-10762.
55. Feng, X.; Becker, K.P.; Stribling, S.D.; Peters, K.G.; Hannun, Y.A. Regulation of receptor-mediated protein kinase C membrane trafficking by autophosphorylation. J. Biol. Chem., 2000, 275(22), 17024-17034.
56. Takahashi, H.; Suzuki, K.; Namiki, H. Pervanadate-induced reverse translocation and tyrosine phosphorylation of phorbol esterstimulated protein kinase C betaII are mediated by Src-family tyrosine kinases in porcine neutrophils. Biochem. Biophys. Res. Commun., 2004, 314(3), 830-837.
57. Violin, J.D.; Zhang, J.; Tsien, R.Y.; Newton, A.C. A genetically encoded fluorescent reporter reveals oscillatory phosphorylation by protein kinase C. J. Cell Biol., 2003, 161(5), 899-909.
58. Gallegos, L.L.; Newton, A.C. Spatiotemporal dynamics of lipid signaling: protein kinase C as a paradigm. IUBMB Life, 2008, 60(12), 782-789.
59. Miele, C.; Paturzo, F.; Teperino, R.; Sakane, F.; Fiory, F.; Oriente, F.; Ungaro, P.; Valentino, R.; Beguinot, F.; Formisano, P., Glucose regulates diacylglycerol intracellular levels and protein kinase C activity by modulating diacylglycerol kinase subcellular localization. J. Biol. Chem., 2007, 282(44), 31835-31843.
60. Luo, B.; Regier, D.S.; Prescott, S.M.; Topham, M.K. Diacylglycerol kinases. Cell. Signal., 2004, 16 (9), 983-999.
61. Topham, M.K. Signaling roles of diacylglycerol kinases. J. Cell. Biochem., 2006, 97(3), 474-484.
62. Topham, M.K.; Prescott, S.M. Diacylglycerol kinases: regulation and signaling roles. Thromb. Haemost., 2002, 88 (6), 912-918.
63. Luo, B.; Prescott, S.M.; Topham, M.K.; Protein kinase C alpha phosphorylates and negatively regulates diacylglycerol kinase zeta. J. Biol. Chem., 2003, 278(41), 39542-39547.
64. Kishimoto, A.; Mikawa, K.; Hashimoto, K.; Yasuda, I.; Tanaka, S.; Tominaga, M.; Kuroda, T.; Nishizuka, Y. Limited proteolysis of protein kinase C subspecies by calcium-dependent neutral protease (calpain). J. Biol. Chem., 1989, 264(7), 4088-4092.
65. Catherine, A.; O'Brian, J.R.S.; Nancy, E.; Ward, P.J.B. Regulatory Mechanisms Governing Protein Kinase C Signaling. Electr. J. Pathol. Histol., 2000, 6(1), 10.
66. Gysin, S.; Imber, R. Replacement of Ser657 of protein kinase C-alpha by alanine leads to premature down regulation after phorbol-ester-induced translocation to the membrane. Eur. J. Biochem., 1996, 240(3), 747-750.
67. Borner, C.; Filipuzzi, I.; Wartmann, M.; Eppenberger, U.; Fabbro, D. Biosynthesis and posttranslational modifications of protein kinase C in human breast cancer cells. J. Biol. Chem., 1989, 264(23), 13902-13909.
68. Lee, H.W.; Smith, L.; Pettit, G.R.; Bingham Smith, J. Dephosphorylation of activated protein kinase C contributes to downregulation by bryostatin. Am. J. Physiol., 1996, 271 (1 Pt 1), C304-11.
69. Bynagari, Y.S.; Nagy, B, Jr.; Tuluc, F.; Bhavaraju, K.; Kim, S.; Vijayan, K.V.; Kunapuli, S.P. Mechanism of activation and functional role of protein kinase Ceta in human platelets. J. Biol. Chem., 2009, 284(20), 13413-13421.
70. Nunbhakdi-Craig, V.; Machleidt, T.; Ogris, E.; Bellotto, D.; White, C.L.; Sontag, E. Protein phosphatase 2A associates with and regulates atypical PKC and the epithelial tight junction complex. J. Cell. Biol., 2002, 158(5), 967-978.
71. Gao, T.; Brognard, J.; Newton, A.C. The phosphatase PHLPP controls the cellular levels of protein kinase C. J. Biol. Chem., 2008, 283(10), 6300-6311.
72. Chen, D.; Gould, C.; Garza, R.; Gao, T.; Hampton, R.Y.; Newton, A.C. Amplitude control of protein kinase C by RINCK, a novel E3 ubiquitin ligase. J. Biol. Chem., 2007, 282(46), 33776-33787.
73. Lu, Z.; Liu, D.; Hornia, A.; Devonish, W.; Pagano, M.; Foster, D.A. Activation of protein kinase C triggers its ubiquitination and degradation. Mol. Cell. Biol., 1998, 18(2), 839-845.
74. Kang, B.S.; French, O.G.; Sando, J.J.; Hahn, C.S. Activation-dependent degradation of protein kinase C eta. Oncogene, 2000, 19(37), 4263-4272.
75. Lee, H.W.; Smith, L.; Pettit, G.R.; Vinitsky, A.; Smith, J.B. Ubiquitination of protein kinase C-alpha and degradation by the proteasome. J. Biol. Chem., 1996, 271 (35), 20973-20976.
76. Rogers, S.; Wells, R.; Rechsteiner, M. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science, 1986, 234(4774), 364-368.
77. Medintz, I.; Wang, X.; Hradek, T.; Michels, C.A. A PEST-like sequence in the N-terminal cytoplasmic domain of Saccharomyces maltose permease is required for glucose-induced proteolysis and rapid inactivation of transport activity. Biochemistry, 2000, 39(15), 4518-4526.
78. Lee, H.W.; Smith, L.; Pettit, G.R.; Smith, J.B. Bryostatin 1 and phorbol ester down-modulate protein kinase C-alpha and -epsilon via the ubiquitin/proteasome pathway in human fibroblasts. Mol. Pharmacol., 1997, 51(3), 439-447.
79. Mischiati, C.; Melloni, E.; Corallini, F.; Milani, D.; Bergamini, C.; Vaccarezza, M. Potential role of PKC inhibitors in the treatment of hematological malignancies. Curr. Pharm. Des., 2008, 14(21), 2075-2084.
80. Dempsey, E.C.; Newton, A.C.; Mochly-Rosen, D.; Fields, A.P.; Reyland, M.E.; Insel, P.A.; Messing, R.O. Protein kinase C isozymes and the regulation of diverse cell responses. Am. J. Physiol. Lung Cell. Mol. Physiol., 2000, 279(3), L429-438.
81. Chen, L.; Hahn, H.; Wu, G.; Chen, C.H.; Liron, T.; Schechtman, D.; Cavallaro, G.; Banci, L.; Guo, Y.; Bolli, R.; Dorn, G.W.; Mochly-Rosen, D. Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC. Proc. Natl. Acad. Sci. USA, 2001, 98(20), 11114-11119.
82. Churchill, E.N.; Mochly-Rosen, D. The roles of PKCdelta and epsilon isoenzymes in the regulation of myocardial ischaemia/reperfusion injury. Biochem. Soc. Trans., 2007, 35(Pt 5), 1040-1042.
83. Gutcher, I.; Webb, P.R.; Anderson, N.G. The isoformspecific regulation of apoptosis by protein kinase C. Cell. Mol. Life Sci., 2003, 60(6), 1061-1070.
84. Dorn, G.W.; Souroujon, M.C.; Liron, T.; Chen, C.H.; Gray, M.O.; Zhou, H.Z.; Csukai, M.; Wu, G.; Lorenz, J. N.; Mochly-Rosen, D. Sustained in vivo cardiac protection by a rationally designed peptide that causes epsilon protein kinase C translocation. Proc. Natl. Acad. Sci. USA, 1999, 96(22), 12798-12803.
85. Budas, G.R.; Koyanagi, T.; Churchill, E.N.; Mochly-Rosen, D. Competitive inhibitors and allosteric activators of protein kinase C isoenzymes: a personal account and progress report on transferring academic discoveries to the clinic. Biochem. Soc. Trans., 2007, 35 (Pt 5), 1021-1026.
86. Irie, K.; Nakagawa, Y.; Ohigashi, H. Indolactam and benzolactam compounds as new medicinal leads with binding selectivity for C1 domains of protein kinase C isozymes. Curr. Pharm. Des., 2004, 10(12), 1371-1385.
87. Kuchtey, J.; Fewtrell, C. Protein kinase C activator PMA reduces the Ca(2+) response to antigen stimulation of adherent RBL-2H3 mucosal mast cells by inhibiting depletion of intracellular Ca(2+) stores. J. Cell. Physiol., 1999, 181(1), 113-123.
88. Barbosa, L.A.; Goto-Silva, L.; Redondo, P.A.; Oliveira, S.; Montesano, G.; De Souza, W.; Morgado-Diaz, J.A. TPA-induced signal transduction: a link between PKC and EGFR signaling modulates the assembly of intercellular junctions in Caco-2 cells. Cell Tissue Res., 2003, 312(3), 319-331.
89. Beutler J.A.; A.B.A.; T.G. McCloud.; G.M. Cragg. Distribution of phorbol ester bioactivity in the euphorbiaceae. Phytother. Res., 1989, 3, 188-192.
90. Strair, R.K.; Schaar, D.; Goodell, L.; Aisner, J.; Chin, K.V.; Eid, J.; Senzon, R.; Cui, X.X.; Han, Z.T.; Knox, B.; Rabson, A.B.; Chang, R.; Conney, A. Administration of a phorbol ester to patients with hematological malignancies: preliminary results from a phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate. Clin. Cancer Res., 2002, 8(8), 2512-2518.
91. Mastro, A.M.; Pepin, K.G. Effect of macrophages on phorbol ester-stimulated comitogenesis in bovine lymphocytes. Cancer Res., 1982, 42(5), 1630-1635.
92. Mastro, A.M.; Pepin, K.G. Effects of 12-O-tetradecanoylphorbol-13-acetate on lymphocyte proliferation. Carcinog. Compr. Surv., 1982, 7, 439-442.
93. Mastro, A.M.; Pepin, K.G. The effects of retinoic acid and a tumor promoter, 12-Otetradecanoylphorbol-13-acetate, on lymphocyte proliferation. Carcinogenesis, 1982, 3 (4), 409-413.
94. Mastro, A.M.; Smith, M.C. Calcium-dependent activation of lymphocytes by ionophore, A23187, and a phorbol ester tumor promoter. J. Cell. Physiol., 1983, 116(1), 51-56.
95. Marks, F.; Furstenberger, G.; Kownatzki, E. Prostaglandin E-mediated mitogenic stimulation of mouse epidermis in vivo by divalent cation ionophore A 23187 and by tumor promoter 12-O-tetradecanoylphorbol-13-acetate. Cancer Res., 1981, 41(2), 696-702.
96. Wang, S.; Liu, M.; Lewin, N.E.; Lorenzo, P.S.; Bhattacharrya, D.; Qiao, L.; Kozikowski, A.P.; Blumberg, P.M. Probing the binding of indolactam-V to protein kinase C through site-directed mutagenesis and computational docking simulations. J. Med. Chem., 1999, 42(18), 3436-3446.
97. Moore, R.E., Toxins, anticancer agents, and tumor promoters from marine prokaryotes. Pure Appl. Chem., 1982, 54, 1919-1934.
98. Gschwendt, M.; Furstenberger, G.; Rose-John, S.; Rogers, M.; Kittstein, W.; Pettit, G. R.; Herald, C.L.; Marks, F. Bryostatin 1, an activator of protein kinase C, mimics as well as inhibits biological effects of the phorbol ester TPA in vivo and in vitro. Carcinogenesis, 1988, 9(4), 555-562.
99. Steube, K.G.; Drexler, H.G. Differentiation and growth modulation of myeloid leukemia cells by the protein kinase C activating agent bryostatin-1. Leuk. Lymphoma, 1993, 9(1-2), 141-148.
100. Varterasian, M.L.; Mohammad, R.M.; Eilender, D.S.; Hulburd, K.; Rodriguez, D.H.; Pemberton, P.A.; Pluda, J.M.; Dan, M.D.; Pettit, G.R.; Chen, B.D.; Al-Katib, A.M. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J. Clin. Oncol., 1998, 16(1), 56-62.
101. Roberts, J.D.; Smith, M.R.; Feldman, E.J.; Cragg, L.; Millenson, M.M.; Roboz, G.J.; Honeycutt, C.; Thune, R.; Padavic-Shaller, K.; Carter, W.H.; Ramakrishnan, V.; Murgo, A.J.; Grant, S. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma. Clin. Cancer Res., 2006, 12(19), 5809-5816.
102. Varterasian, M.L.; Mohammad, R.M.; Shurafa, M.S.; Hulburd, K.; Pemberton, P.A.; Rodriguez, D.H.; Spadoni, V.; Eilender, D.S.; Murgo, A.; Wall, N.; Dan, M.; Al-Katib, A.M. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin. Cancer Res., 2000, 6(3), 825-828.
103. Kim, H.H.; Ahn, K.S.; Han, H.; Choung, S.Y.; Choi, S.Y.; Kim, I.H. Decursin and PDBu: two PKC activators distinctively acting in the megakaryocytic differentiation of K562 human erythroleukemia cells. Leuk. Res., 2005, 29(12), 1407-1413.
104. Kim, H.H.; Sik Bang, S.; Seok Choi, J.; Han, H.; Kim, I.H. Involvement of PKC and ROS in the cytotoxic mechanism of anti-leukemic decursin and its derivatives and their structureactivity relationship in human K562 erythroleukemia and U937 myeloleukemia cells. Cancer Lett., 2005, 223(2), 191-201.
105. Chong, S.Y.; Kim, I.H.; Ahn, K.S.; Kim, S.K. A pharmaceutical composition comprising decursin and its uses as a nephrotoxicity inhibitor, an antineoplastic agent, an antidiabetic agent, and as a cancer-cell differentiation induction agent are disclosed. United States Patent, 6525089, 2003.
106. Singh, R.P.; Agarwal, R. Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr. Relat. Cancer, 2006, 13(3), 751-778.
107. Ohshima, T. Enantioselective total syntheses of several bioactive natural products based on the development of practical asymmetric catalysis. Chem. Pharm. Bull. (Tokyo), 2004, 52(9), 1031-1052.
108. O'Flaherty, J.T.; Redman, J.F.; Jacobson, D.P. Mechanisms involved in the bidirectional effects of protein kinase C activators on neutrophil responses to leukotriene B4. J. Immunol., 1990, 144(5), 1909-1913.
109. Nishio, H.; Ikegami, Y.; Segawa, T.; Nakata, Y. Stimulation of calcium sequestration by mezerein, a protein kinase C activator, in saponized rabbit platelets. Gen. Pharmacol., 1994, 25(3), 413-416.
110. Ronlan, A.; Wickberg, B. The structure of mezerein, a major toxic principle of Daphne mezereum L. Tetrahedron Lett., 1970, 49, 4261-4264.
111. Serova, M.; Ghoul, A.; Benhadji, K. A.; Cvitkovic, E.; Faivre, S.; Calvo, F.; Lokiec, F.; Raymond, E. Preclinical and clinical development of novel agents that target the protein kinase C family. Semin. Oncol., 2006, 33(4), 466-478.
112. Oh, Y.I.; Kim, J.H.; Kang, C.W. Oxidative stress in MCF-7 cells is involved in the effects of retinoic acid-induced activation of protein kinase C-delta on insulin-like growth factor-I secretion and synthesis. Growth Horm. IGF. Res., 2010, 20(2), 101-109.
113. Houston, D.S. Tissue factor - a therapeutic target for thrombotic disorders. Expert Opin. Ther. Targets, 2002, 6(2), 159-174.
114. Wilkinson, S.E.; Parker, P.J.; Nixon, J.S. Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C. Biochem. J., 1993, 294(2), 335-337.
115. Toullec, D.; Pianetti, P.; Coste, H.; Bellevergue, P.; Gravd-Perret, T.; Ajakane, M.; Baudet, V.; Boissin, P.; Boursier, E.; Loriolle, F., The Bisindolylmaleimide GF 109203X Is a Potent and Selective Printed in U.S.A. Inhibitor of Protein Kinase C. J. Biol. Chem., 1991, 266(24), 15771-15781.
116. Davies, S.P.; Reddy, H.; Caivano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J., 2000, 351 (1), 95-105.
117. Yamamoto, N.; Hasegawa, H.; Seki, H.; Ziegelbauer, K.; Yasuda, T. Development of a high-throughput fluoroimmunoassay for Syk kinase and Syk kinase inhibitors. Anal. Biochem., 2003, 315(2), 256-261.
118. Straub, S.G.; Sharp, G.W. Massive augmentation of stimulated insulin secretion induced by fatty acid-free BSA in rat pancreatic islets. Diabetes, 2004, 53(12), 3152-3158.
119. Kozikowski, A.P.; Wang, S.; Ma, D.; Yao, J.; Ahmad, S.; Glazer, R.I.; Bogi, K.; Acs, P.; Modarres, S.; Lewin, N.E.; Blumberg, P.M. Modeling, chemistry, and biology of the benzolactam analogues of indolactam V (ILV). 2. Identification of the binding site of the benzolactams in the CRD2 activator-binding domain of PKCdelta and discovery of an ILV analogue of improved isozyme selectivity. J. Med. Chem., 1997, 40(9), 1316-1326.
120. Davis, M.D.; Sheetz, M.J.; Aiello, L.P.; Milton, R.C.; Danis, R.P.; Zhi, X.; Girach, A.; Jimenez, M.C.; Vignati, L. Effect of ruboxistaurin on the visual acuity decline associated with longstanding diabetic macular edema. Invest. Ophthalmol. Vis. Sci., 2009, 50(1), 1-4.
121. Aiello, L.P.; Davis, M.D.; Girach, A.; Kles, K.A.; Milton, R.C.; Sheetz, M.J.; Vignati, L.; Zhi, X.E. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology, 2006, 113(12), 2221-2230.
122. Yanagita, R.C.; Nakagawa, Y.; Yamanaka, N.; Kashiwagi, K.; Saito, N.; Irie, K. Synthesis, conformational analysis, and biological evaluation of 1-hexylindolactam-V10 as a selective activator for novel protein kinase C isozymes. J. Med. Chem., 2008, 51(1), 46-56.
123. Ebanks, R.; Roifman, C.; Mellors, A.; Mills, G. B. The diacylglycerol analogue, 1,2-sn-dioctanoylglycerol, induces an increase in cytosolic free Ca2+ and cytosolic acidification of T lymphocytes through a protein kinase C-independent process. Biochem. J., 1989, 258(3), 689-698.
124. Kazanietz, M.G. Targeting protein kinase C and non-kinase phorbol ester receptors: emerging concepts and therapeutic implications. Biochim. Biophys. Acta., 2005, 1754 (1-2), 296-304.
125. Ma, D.; Tang, G.; Kozikowski, A.P. Synthesis of 7-substituted benzolactam-V8s and their selectivity for protein kinase C isozymes. Org. Lett., 2002, 4(14), 2377-2380.
126. Nakagawa, Y.; Irie, K.; Yanagita, R.C.; Ohigashi, H.; Tsuda, K.; Kashiwagi, K.; Saito, N. Design and synthesis of 8-octylbenzolactam-V9, a selective activator for protein kinase C epsilon and eta. J. Med. Chem., 2006, 49(9), 2681-2688.
127. Coutinho, I.; Pereira, G.; Simoes, M. F.; Corte-Real, M.; Goncalves, J.; Saraiva, L. Selective activation of protein kinase C-delta and -epsilon by 6,11,12,14-tetrahydroxy-abieta-5,8,11,13-tetraene-7-one (coleon U). Biochem. Pharmacol., 2009, 78 (5), 449-459.
128. Kim, M.Y.; Kim, M.J.; Yoon, I.S.; Ahn, J.H.; Lee, S.H.; Baik, E.J.; Moon, C.H.; Jung, Y.S. Diazoxide acts more as a PKC-epsilon activator, and indirectly activates the mitochondrial K(ATP) channel conferring cardioprotection against hypoxic injury. Br. J. Pharmacol., 2006, 149(8), 1059-1070.
129. van Hamersvelt, H.W.; Kloke, H.J.; de Jong, D.J.; Koene, R.A.; Huysmans, F.T. Oedema formation with the vasodilators nifedipine and diazoxide: direct local effect or sodium retention? J. Hypertens., 1996, 14(8), 1041-1055.
130. Guo, Z.; Bu, S.; Yu, Y.; Ghatnekar, G.; Wang, M.; Chen, L.; Bu, M.; Yang, L.; Zhu, B.; Feng, Z.; Huang, Q. Diazoxide prevents abdominal adiposity and fatty liver in obese OLETF rats at prediabetic stage. J. Diabetes Complications, 2008, 22(1), 46-55.
131. Huang, Q.; Bu, S.; Yu, Y.; Guo, Z.; Ghatnekar, G.; Bu, M.; Yang, L.; Lu, B.; Feng, Z.; Liu, S.; Wang, F. Diazoxide prevents diabetes through inhibiting pancreatic beta-cells from apoptosis via Bcl-2/Bax rate and p38-beta mitogen-activated protein kinase. Endocrinology, 2007, 148(1), 81-91.
132. Wei, W.; Wei, F.C.; Hung, L.M. Diazoxide ameliorates microcirculatory disturbances through PKC-dependent pathway in I/R-injured rat cremaster muscles. J. Biomed. Sci., 2005, 12(3), 521-529.
133. Inagaki, K.; Hahn, H.S.; Dorn, G.W.; Mochly-Rosen, D. Additive protection of the ischemic heart ex vivo by combined treatment with delta-protein kinase C inhibitor and epsilon-protein kinase C activator. Circulation, 2003, 108(7), 869-875.
134. Eichholtz, T.; de Bont, D.B.; de Widt, J.; Liskamp, R.M.; Ploegh, H.L. A myristoylated pseudosubstrate peptide, a novel protein kinase C inhibitor. J. Biol. Chem., 1993, 268(3), 1982-1986.
135. Ward, N.E.; O'Brian, C.A. Inhibition of protein kinase C by Nmyristoylated peptide substrate analogs. Biochemistry, 1993, 32(44), 11903-11909.
136. Phillipson, A.; Peterman, E.E.; Taormina, P. Jr.; Harvey, M.; Brue, R.J.; Atkinson, N.; Omiyi, D.; Chukwu, U.; Young, L.H. Protein kinase C-zeta inhibition exerts cardioprotective effects in ischemiareperfusion injury. Am. J. Physiol. Heart Circ. Physiol., 2005, 289(2), H898-907.
137. Trujillo, J.I.; Kiefer, J.R.; Huang, W.; Thorarensen, A.; Xing, L.; Caspers, N.L.; Day, J.E.; Mathis, K.J.; Kretzmer, K.K.; Reitz, B.A.; Weinberg, R.A.; Stegeman, R.A.; Wrightstone, A.; Christine, L.; Compton, R.; Li, X. 2-(6-Phenyl-1H-indazol-3-yl)-1Hbenzo[ d]imidazoles: design and synthesis of a potent and isoform selective PKC-zeta inhibitor. Bioorg. Med. Chem. Lett., 2009, 19(3), 908-911.
138. Erdbrugger, W.; Keffel, J.; Knocks, M.; Otto, T.; Philipp, T.; Michel, M.C. Protein kinase C isoenzymes in rat and human cardiovascular tissues. Br. J. Pharmacol., 1997, 120(2), 177-186.
139. Rouet-Benzineb, P.; Mohammadi, K.; Perennec, J.; Poyard, M.; Bouanani Nel, H.; Crozatier, B. Protein kinase C isoform expression in normal and failing rabbit hearts. Circ. Res., 1996, 79(2), 153-161.
140. Bowling, N.; Walsh, R.A.; Song, G.; Estridge, T.; Sandusky, G.E.; Fouts, R.L.; Mintze, K.; Pickard, T.; Roden, R.; Bristow, M.R.; Sabbah, H.N.; Mizrahi, J.L.; Gromo, G.; King, G.L.; Vlahos, C.J. Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation, 1999, 99(3), 384-391.
141. Glass, C.K.; Witztum, J.L. Atherosclerosis. the road ahead. Cell, 2001, 104(4), 503-516.
142. Plutzky, J. The vascular biology of atherosclerosis. Am. J. Med., 2003, 115(Suppl 8A), 55S-61S.
143. Parthasarathy, S.; Quinn, M.T.; Schwenke, D.C.; Carew, T.E.; Steinberg, D. Oxidative modification of beta-very low density lipoprotein. Potential role in monocyte recruitment and foam cell formation. Arteriosclerosis, 1989, 9(3), 398-404.
144. Navab, M.; Berliner, J.A.; Watson, A.D.; Hama, S.Y.; Territo, M.C.; Lusis, A.J.; Shih, D.M.; Van Lenten, B.J.; Frank, J.S.; Demer, L.L.; Edwards, P.A.; Fogelman, A.M., The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler. Thromb. Vasc. Biol., 1996, 16 (7), 831-842.
145. Behr-Roussel, D.; Rupin, A.; Simonet, S.; Bonhomme, E.; Coumailleau, S.; Cordi, A.; Serkiz, B.; Fabiani, J.N.; Verbeuren, T.J. Effect of chronic treatment with the inducible nitric oxide synthase inhibitor N-iminoethyl-L-lysine or with L-arginine on progression of coronary and aortic atherosclerosis in hypercholesterolemic rabbits. Circulation, 2000, 102(9), 1033-1038.
146. Behr-Roussel, D.; Rupin, A.; Sansilvestri-Morel, P.; Fabiani, J.N.; Verbeuren, T.J. Histochemical evidence for inducible nitric oxide synthase in advanced but non-ruptured human atherosclerotic carotid arteries. Histochem. J., 2000, 32(1), 41-51.
147. Bocan, T.M.; Rosebury, W.S.; Mueller, S.B.; Kuchera, S.; Welch, K.; Daugherty, A.; Cornicelli, J.A. A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit. Atherosclerosis, 1998, 136(2), 203-216.
148. Bird, D.A.; Gillotte, K.L.; Horkko, S.; Friedman, P.; Dennis, E.A.; Witztum, J.L.; Steinberg, D. Receptors for oxidized low-density lipoprotein on elicited mouse peritoneal macrophages can recognize both the modified lipid moieties and the modified protein moieties: implications with respect to macrophage recognition of apoptotic cells. Proc. Natl. Acad. Sci. USA, 1999, 96(11), 6347-6352.
149. Reiner, Z.; Tedeschi-Reiner, E. New information on the pathophysiology of atherosclerosis. Lijec Vjesn, 2001, 123(1-2), 26-31.
150. Johnson, J.L. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Rev. Cardiovasc. Ther., 2007, 5 (2), 265-282.
151. Churchill, E.; Budas, G.; Vallentin, A.; Koyanagi, T.; Mochly-Rosen, D. PKC isozymes in chronic cardiac disease: possible therapeutic targets? Annu. Rev. Pharmacol. Toxicol., 2008, 48, 569-599.
152. Stapf, C.; Mohr, J.P. Ischemic stroke therapy. Annu. Rev. Med., 2002, 53, 453-75.
153. Stapf, C.; Labovitz, D.L.; Sciacca, R.R.; Mast, H.; Mohr, J.P.; Sacco, R.L. Incidence of adult brain arteriovenous malformation hemorrhage in a prospective population-based stroke survey. Cerebrovasc. Dis., 2002, 13 (1), 43-46.
154. Chou, W.H.; Messing, R.O. Protein kinase C isozymes in stroke. Trends Cardiovasc. Med., 2005, 15 (2), 47-51.
155. Cohen, M.V.; Walsh, R.S.; Goto, M.; Downey, J.M. Hypoxia preconditions rabbit myocardium via adenosine and catecholamine release. J. Mol. Cell. Cardiol., 1995, 27(8), 1527-1534.
156. Vegh, A.; Szekeres, L.; Parratt, J.R. Transient ischaemia induced by rapid cardiac pacing results in myocardial preconditioning. Cardiovasc. Res., 1991, 25(12), 1051-3.
157. Koning, M.M.; Gho, B.C.; van Klaarwater, E.; Opstal, R.L.; Duncker, D.J.; Verdouw, P.D. Rapid ventricular pacing produces myocardial protection by nonischemic activation of KATP+ channels. Circulation, 1996, 93(1), 178-186.
158. Cumming, D.V.; Heads, R.J.; Brand, N.J.; Yellon, D.M.; Latchman, D.S. The ability of heat stress and metabolic preconditioning to protect primary rat cardiac myocytes. Basic Res. Cardiol., 1996, 91(1), 79-85.
159. Ovize, M.; Kloner, R.A.; Przyklenk, K. Stretch preconditions canine myocardium. Am. J. Physiol., 1994, 266(1 Pt 2), H137-46.
160. Gysembergh, A.; Margonari, H.; Loufoua, J.; Ovize, A.; Andre-Fouet, X.; Minaire, Y.; Ovize, M. Stretch-induced protection shares a common mechanism with ischemic preconditioning in rabbit heart. Am. J. Physiol., 1998, 274(3 Pt 2), H955-64.
161. Nakano, A.; Cohen, M.V.; Downey, J.M. Ischemic preconditioning: from basic mechanisms to clinical applications. Pharmacol. Ther., 2000, 86(3), 263-275.
162. Kavanagh, C.A.; Rochev, Y.A.; Gallagher, W.M.; Dawson, K.A.; Keenan, A.K. Local drug delivery in restenosis injury: thermoresponsive copolymers as potential drug delivery systems. Pharmacol. Ther., 2004, 102(1), 1-15.
163. Ping, P.; Zhang, J.; Qiu, Y.; Tang, X.L.; Manchikalapudi, S.; Cao, X.; Bolli, R. Ischemic preconditioning induces selective translocation of protein kinase C isoforms epsilon and eta in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity. Circ. Res., 1997, 81(3), 404-414.
164. Yoshida, K.; Kawamura, S.; Mizukami, Y.; Kitakaze, M. Implication of protein kinase C-alpha, delta, and epsilon isoforms in ischemic preconditioning in perfused rat hearts. J. Biochem., 1997, 122(3), 506-511.
165. Kitakaze, M.; Funaya, H.; Minamino, T.; Node, K.; Sato, H.; Ueda, Y.; Okuyama, Y.; Kuzuya, T.; Hori, M.; Yoshida, K. Role of protein kinase C-alpha in activation of ecto-5'-nucleotidase in the preconditioned canine myocardium. Biochem. Biophys. Res. Commun., 1997, 239 (1), 171-175.
166. Lipton, P. Ischemic cell death in brain neurons. Physiol. Rev., 1999, 79(4), 1431-1568.
167. Phan, T.G.; Huston, J.; Campeau, N.G.; Brown, R.D. Jr.; Fulgham, J.R.; Wijdicks, E.F. Early evolution of deficits in acute ischemic stroke: mean transit time, relative blood volume, and relative blood flow. J. Stroke Cerebrovasc. Dis., 2002, 11(2), 66-71.
168. Yang, G.Y.; Betz, A.L. Reperfusion-induced injury to the blood-brain barrier after middle cerebral artery occlusion in rats. Stroke, 1994, 25 (8), 1658-64.;discussion 1664-5.
169. Yang, G. Y.; Betz, A.L.; Chenevert, T.L.; Brunberg, J.A.; Hoff, J.T. Experimental intracerebral hemorrhage: relationship between brain edema, blood flow, and blood-brain barrier permeability in rats. J. Neurosurg., 1994, 81(1), 93-102.
170. Matsumoto, S.; Shamloo, M.; Matsumoto, E.; Isshiki, A.; Wieloch, T. Protein kinase C-gamma and calcium/calmodulindependent protein kinase II-alpha are persistently translocated to cell membranes of the rat brain during and after middle cerebral artery occlusion. J. Cereb. Blood. Flow. Metab., 2004, 24(1), 54-61.
171. Kowalczyk, J.E.; Zablocka, B. Protein kinases in mitochondria. Postepy. Biochem., 2008, 54(2), 209-216.
172. Speechly-Dick, M.E.; Mocanu, M.M.; Yellon, D.M. Protein kinase C. Its role in ischemic preconditioning in the rat. Circ. Res., 1994, 75(3), 586-590.
173. Raval, A.P.; Dave, K.R.; Mochly-Rosen, D.; Sick, T.J.; Perez-Pinzon, M.A. Epsilon PKC is required for the induction of tolerance by ischemic and NMDA-mediated preconditioning in the organotypic hippocampal slice. J. Neurosci., 2003, 23(2), 384-391.
174. Piccoletti, R.; Bendinelli, P.; Arienti, D.; Bernelli-Zazzera, A. State and activity of protein kinase C in postischemic reperfused liver. Exp. Mol. Pathol., 1992, 56(3), 219-228.
175. Padanilam, B. J. Induction and subcellular localization of protein kinase C isozymes following renal ischemia. Kidney Int., 2001, 59(5), 1789-1797.
176. Bright, R.; Raval, A.P.; Dembner, J.M.; Perez-Pinzon, M.A.; Steinberg, G.K.; Yenari, M.A.; Mochly-Rosen, D. Protein kinase C delta mediates cerebral reperfusion injury in vivo. J. Neurosci., 2004, 24(31), 6880-6888.
177. Lange-Asschenfeldt, C.; Raval, A.P.; Dave, K.R.; Mochly-Rosen, D.; Sick, T.J.; Perez-Pinzon, M.A. Epsilon protein kinase C mediated ischemic tolerance requires activation of the extracellular regulated kinase pathway in the organotypic hippocampal slice. J. Cereb. Blood Flow Metab., 2004, 24 (6), 636-645.
178. Chou, W.H.; Choi, D.S.; Zhang, H.; Mu, D.; McMahon, T.; Kharazia, V.N.; Lowell, C.A.; Ferriero, D.M.; Messing, R.O. Neutrophil protein kinase Cdelta as a mediator of stroke-reperfusion injury. J. Clin. Invest., 2004, 114 (1), 49-56.
179. Aronowski, J.; Labiche, L.A. Perspectives on reperfusioninduced damage in rodent models of experimental focal ischemia and role of gamma-protein kinase C. ILAR J., 2003, 44(2), 105-109.
180. Aronowski, J.; Grotta, J.C.; Strong, R.; Waxham, M.N. Interplay between the gamma isoform of PKC and calcineurin in regulation of vulnerability to focal cerebral ischemia. J. Cereb. Blood Flow Metab., 2000, 20(2), 343-349.
181. Lawrence, F.; Brass, T.J.S.; Li, Zhu.; Donna, S.W. Signal Transduction During Platelet Plug Formation, 2ed.; Elsevier: Massachusetts, 2002; p. 1343.
182. Banfi, C.; Brioschi, M.; Marenzi, G.; De Metrio, M.; Camera, M.; Mussoni, L.; Tremoli, E. Proteome of platelets in patients with coronary artery disease. Exp. Hematol., 2010, 38(5), 341-350.
183. Matsagas, M.I.; Geroulakos, G.; Mikhailidis, D.P. The role of platelets in peripheral arterial disease: therapeutic implications. Ann. Vasc. Surg., 2002, 16 (2), 246-258.
184. Maekawa, T.; Kobayashi, N. Etiology of thromboembolism and the role of blood platelets. Nippon Rinsho., 1978, 36(12), 3764-3770.
185. Smith, N.M.; Pathansali, R.; Bath, P.M., Platelets and stroke. Vasc. Med., 1999, 4(3), 165-172.
186. Puckett, C.L.; Gervin, A.S.; Rhodes, G.R.; Silver, D. Role of platelets and serotonin in acute massive pulmonary embolism. Surg. Gynecol. Obstet., 1973, 137 (4), 618-622.
187. Genton, E. Cardiac thromboembolism: evidence for role of platelets and value of platelet suppressant therapy. Bibl. Haematol., 1977, 44, 188-196.
188. Nofer, J.R.; Brodde, M.F.; Kehrel, B.E. High density lipoproteins (HDL), platelets and the pathogenesis of atherosclerosis. Clin. Exp. Pharmacol. Physiol., 2010, 37(7), 726-735.
189. Quinton, T.M.; Ozdener, F.; Dangelmaier, C.; Daniel, J.L.; Kunapuli, S. P. Glycoprotein VI-mediated platelet fibrinogen receptor activation occurs through calcium-sensitive and PKCsensitive pathways without a requirement for secreted ADP. Blood, 2002, 99(9), 3228-3234.
190. Quinton, T.M.; Kim, S.; Dangelmaier, C.; Dorsam, R.T.; Jin, J.; Daniel, J.L.; Kunapuli, S.P. Protein kinase C- and calcium-regulated pathways independently synergize with Gi pathways in agonist-induced fibrinogen receptor activation. Biochem. J., 2002, 368(2), 535-543.
191. Tsukuda, M.; Asaoka, Y.; Sekiguchi, K.; Kikkawa, U.; Nishizuka, Y. Properties of protein kinase C subspecies in human platelets. Biochem. Biophys. Res. Commun., 1988, 155(3), 1387-1395.
192. Pollock, W.K.; Sage, S.O.; Rink, T.J. Stimulation of Ca2+ efflux from fura-2-loaded platelets activated by thrombin or phorbol myristate acetate. FEBS Lett., 1987, 210(2), 132-136.
193. King, W.G.; Downes, C.P.; Prestwich, G.D.; Rittenhouse, S.E. Ca2(+)-stimulatable and protein kinase C-inhibitable accumulation of inositol 1,3,4,6-tetrakisphosphate in human platelets. Biochem. J., 1990, 270 (1), 125-131.
194. Rink, T.J.; Sanchez, A.; Hallam, T.J. Diacylglycerol and phorbol ester stimulate secretion without raising cytoplasmic free calcium in human platelets. Nature, 1983, 305(5932), 317-319.
195. Walker, T.R.; Watson, S.P. Synergy between Ca2+ and protein kinase C is the major factor in determining the level of secretion from human platelets. Biochem. J., 1993, 289(1), 277-272.
196. Yoshioka, A.; Shirakawa, R.; Nishioka, H.; Tabuchi, A.; Higashi, T.; Ozaki, H.; Yamamoto, A.; Kita, T.; Horiuchi, H. Identification of protein kinase Calpha as an essential, but not sufficient, cytosolic factor for Ca2+-induced alpha-and dense-core granule secretion in platelets. J. Biol. Chem., 2001, 276(42), 39379-39385.
197. Cifuni, S.M.; Wagner, D.D.; Bergmeier, W. CalDAG-GEFI and protein kinase C represent alternative pathways leading to activation of integrin alphaIIbbeta3 in platelets. Blood, 2008, 112(5), 1696-1703.
198. Strehl, A.; Munnix, I.C.; Kuijpers, M.J.; van der Meijden, P.E.; Cosemans, J.M.; Feijge, M.A.; Nieswandt, B.; Heemskerk, J.W. Dual role of platelet protein kinase C in thrombus formation: stimulation of pro-aggregatory and suppression of procoagulant activity in platelets. J. Biol. Chem., 2007, 282(10), 7046-7055.
199. Polanowska-Grabowska, R.; Gear, A.R. Activation of protein kinase C is required for the stable attachment of adherent platelets to collagen but is not needed for the initial rapid adhesion under flow conditions. Arterioscler. Thromb. Vasc. Biol., 1999, 19(12), 3044-3054.
200. Haimovich, B.; Kaneshiki, N.; Ji, P. Protein kinase C regulates tyrosine phosphorylation of pp125FAK in platelets adherent to fibrinogen. Blood, 1996, 87(1), 152-161.
201. Buensuceso, C.S.; Obergfell, A.; Soriani, A.; Eto, K.; Kiosses, W.B.; Arias-Salgado, E.G.; Kawakami, T.; Shattil, S.J. Regulation of outside-in signaling in platelets by integrin-associated protein kinase C beta. J. Biol. Chem., 2005, 280(1), 644-653.
202. Soriani, A.; Moran, B.; de Virgilio, M.; Kawakami, T.; Altman, A.; Lowell, C.; Eto, K.; Shattil, S.J. A role for PKCtheta in outside-in alpha(IIb)beta3 signaling. J. Thromb. Haemost., 2006, 4(3), 648-655.
203. Giuliano, S.; Nesbitt, W.S.; Rooney, M.; Jackson, S.P. Bidirectional integrin alphaIIbbeta3 signalling regulating platelet adhesion under flow: contribution of protein kinase C. Biochem. J., 2003, 372(Pt 1), 163-172.
204. Konopatskaya, O.; Gilio, K.; Harper, M.T.; Zhao, Y.; Cosemans, J.M.; Karim, Z.A.; Whiteheart, S.W.; Molkentin, J.D.; Verkade, P.; Watson, S.P.; Heemskerk, J.W.; Poole, A.W. PKCalpha regulates platelet granule secretion and thrombus formation in mice. J. Clin. Invest., 2009, 119(2), 399-407.
205. Chari, R.; Getz, T.; Nagy, B, Jr.; Bhavaraju, K.; Mao, Y.; Bynagari, Y.S.; Murugappan, S.; Nakayama, K.; Kunapuli, S.P. Protein kinase C[delta] differentially regulates platelet functional responses. Arterioscler. Thromb. Vasc. Biol., 2009, 29(5), 699-705.
206. Reaven, G.M. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu. Rev. Nutr., 2005, 25, 391-406.
207. Beckman, J.A.; Creager, M.A.; Libby, P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA, 2002, 287(19), 2570-2581.
208. Meshkani, R.; Adeli, K., Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin. Biochem., 2009, 42(13-14), 1331-1346.
209. Edelman, S.V. Type II diabetes mellitus. Adv. Intern. Med., 1998, 43, 449-500.
210. Triggle, C.R. The early effects of elevated glucose on endothelial function as a target in the treatment of type 2 diabetes. Drugs Today (Barc)., 2007, 43(11), 815-826.
211. Danis, R.P.; Sheetz, M.J. Ruboxistaurin: PKC-beta inhibition for complications of diabetes. Expert Opin. Pharmacother., 2009, 10(17), 2913-2925.
212. Creager, M.A.; Luscher, T.F.; Cosentino, F.; Beckman, J.A. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation, 2003, 108(12), 1527-1532.
213. Kang, N.; Alexander, G.; Park, J.K.; Maasch, C.; Buchwalow, I.; Luft, F.C.; Haller, H. Differential expression of protein kinase C isoforms in streptozotocin-induced diabetic rats. Kidney Int., 1999, 56(5), 1737-1750.
214. Haller, H.; Baur, E.; Quass, P.; Behrend, M.; Lindschau, C.; Distler, A.; Luft, F.C. High glucose concentrations and protein kinase C isoforms in vascular smooth muscle cells. Kidney Int., 1995, 47(4), 1057-1067.
215. Kuboki, K.; Jiang, Z.Y.; Takahara, N.; Ha, S.W.; Igarashi, M.; Yamauchi, T.; Feener, E.P.; Herbert, T.P.; Rhodes, C.J.; King, G.L. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation, 2000, 101(6), 676-681.
216. Ishii, H.; Koya, D.; King, G.L. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J. Mol. Med., 1998, 76(1), 21-31.
217. Ishii, H.; Jirousek, M.R.; Koya, D.; Takagi, C.; Xia, P.; Clermont, A.; Bursell, S.E.; Kern, T.S.; Ballas, L.M.; Heath, W.F.; Stramm, L.E.; Feener, E.P.; King, G.L. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science, 1996, 272(5262), 728-731.
218. Naruse, K.; Rask-Madsen, C.; Takahara, N.; Ha, S.W.; Suzuma, K.; Way, K.J.; Jacobs, J.R.; Clermont, A.C.; Ueki, K.; Ohshiro, Y.; Zhang, J.; Goldfine, A.B.; King, G.L. Activation of vascular protein kinase C-beta inhibits Akt-dependent endothelial nitric oxide synthase function in obesity-associated insulin resistance. Diabetes, 2006, 55(3), 691-698.
219. McGill, J.B.; King, G.L.; Berg, P.H.; Price, K.L.; Kles, K.A.; Bastyr, E.J.; Hyslop, D.L. Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin. Expert Opin. Drug Saf., 2006, 5(6), 835-845.
220. He, Z.; King, G.L. Can protein kinase C beta-selective inhibitor, ruboxistaurin, stop vascular complications in diabetic patients? Diabetes Care, 2005, 28(11), 2803-2805.
221. Inoguchi, T.; Li, P.; Umeda, F.; Yu, H.Y.; Kakimoto, M.; Imamura, M.; Aoki, T.; Etoh, T.; Hashimoto, T.; Naruse, M.; Sano, H.; Utsumi, H.; Nawata, H. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes, 2000, 49(11), 1939-1945.
222. Tesfamariam, B.; Brown, M.L.; Cohen, R.A. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J. Clin. Invest., 1991, 87(5), 1643-1648.
223. Watanabe, Y.; Sunayama, S.; Shimada, K.; Sawano, M.; Hoshi, S.; Iwama, Y.; Mokuno, H.; Daida, H.; Yamaguchi, H. Troglitazone improves endothelial dysfunction in patients with insulin resistance. J. Atheroscler. Thromb., 2000, 7 (3), 159-163.
224. Assert, R.; Scherk, G.; Bumbure, A.; Pirags, V.; Schatz, H.; Pfeiffer, A.F. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. Diabetologia, 2001, 44(2), 188-195.
225. Murugappan, S.; Tuluc, F.; Dorsam, R.T.; Shankar, H.; Kunapuli, S.P. Differential role of protein kinase C delta isoform in agonistinduced dense granule secretion in human platelets. J. Biol. Chem., 2004, 279(4), 2360-2367.
226. Bates, E.; Bode, C.; Costa, M.; Gibson, C.M.; Granger, C.; Green, C.; Grimes, K.; Harrington, R.; Huber, K.; Kleiman, N.; Mochly-Rosen, D.; Roe, M.; Sadowski, Z.; Solomon, S.; Widimsky, P. Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation, 2008, 117(7), 886-896.
227. Metzler, B.; Xu, Q.; Mayr, M. Letter by Metzler et al. regarding article, Intracoronary KAI-9803 as an adjunct to primary coronary intervention for acute ST-segment elevation myocardial infarction. Circulation, 2008, 118(4), e80.
228. Xu, Y.; Ware, J.A. Selective inhibition of thrombin receptormediated Ca2+ entry by protein kinase C beta. J. Biol. Chem., 1995, 270(41), 23887-23890.
229. Przyklenk, K.; Li, G.; Simkhovich, B.Z.; Kloner, R.A. Mechanisms of myocardial ischemic preconditioning are age related: PKCepsilon does not play a requisite role in old rabbits. J. Appl. Physiol., 2003, 95(6), 2563-2569.
230. Shin, H.G.; Barnett, J.V.; Chang, P.; Reddy, S.; Drinkwater, D.C.; Pierson, R.N.; Wiley, R.G.; Murray, K.T. Molecular heterogeneity of protein kinase C expression in human ventricle. Cardiovasc. Res., 2000, 48(2), 285-299.
231. Ganz, M.B.; Seftel, A. Glucose-induced changes in protein kinase C and nitric oxide are prevented by vitamin E. Am. J. Physiol. Endocrinol. Metab., 2000, 278(1), E146-52.
232. Frey, R.S.; Rahman, A.; Kefer, J.C.; Minshall, R.D.; Malik, A.B. PKCzeta regulates TNF-alpha-induced activation of NADPH oxidase in endothelial cells. Circ. Res., 2002, 90(9), 1012-1019.
233. Krizbai, I.; Szabo, G.; Deli, M.; Maderspach, K.; Lehel, C.; Olah, Z.; Wolff, J.R.; Joo, F. Expression of protein kinase C family members in the cerebral endothelial cells. J. Neurochem., 1995, 65(1), 459-462.
234. McNally, A.K.; Macewan, S.R.; Anderson, J.M. Foreign body-type multinucleated giant cell formation requires protein kinase C beta, delta, and zeta. Exp. Mol. Pathol., 2008, 84(1), 37-45.
235. Pears, C.J.; Thornber, K.; Auger, J.M.; Hughes, C.E.; Grygielska, B.; Protty, M.B.; Pearce, A.C.; Watson, S.P. Differential roles of the PKC novel isoforms, PKCdelta and PKCepsilon, in mouse and human platelets. PLoS. One., 2008, 3(11), e3793.
236. Goldberg, M.; Steinberg, S.F. Tissue-specific developmental regulation of protein kinase C isoforms. Biochem. Pharmacol., 1996, 51(8), 1089-1093.
237. Rask-Madsen, C.; King, G.L. Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler. Thromb. Vasc. Biol., 2005, 25(3), 487-496.
238. Ceolotto, G.; Gallo, A.; Miola, M.; Sartori, M.; Trevisan, R.; Del Prato, S.; Semplicini, A.; Avogaro, A. Protein kinase C activity is acutely regulated by plasma glucose concentration in human monocytes in vivo. Diabetes, 1999, 48(6), 1316-1322.
239. Watanabe, T.; Pakala, R.; Katagiri, T.; Benedict, C.R. Monocyte chemotactic protein 1 amplifies serotonin-induced vascular smooth muscle cell proliferation. J. Vasc. Res., 2001, 38(4), 341-349.
240. Carnevale, K.A.; Cathcart, M.K. Protein kinase C beta is required for human monocyte chemotaxis to MCP-1. J. Biol. Chem., 2003, 278(28), 25317-25322.
241. Harper, M.T.; Poole, A.W, Diverse functions of protein kinase C isoforms in platelet activation and thrombus formation. J. Thromb. Haemost., 8(3), 454-462.
242. Kapoor, G.S.; Golden, C.; Atkins, B.; Mehta, K.D. pp90RSKand protein kinase C-dependent pathway regulates p42/44MAPKinduced LDL receptor transcription in HepG2 cells. J. Lipid Res., 2003, 44(3), 584-593.
243. Mehta, K.D.; Radominska-Pandya, A.; Kapoor, G.S.; Dave, B.; Atkins, B.A. Critical role of diacylglycerol-and phospholipid-regulated protein kinase C epsilon in induction of low-density lipoprotein receptor transcription in response to depletion of cholesterol. Mol. Cell. Biol., 2002, 22(11), 3783-3793.
244. Huang, W.; Mishra, V.; Batra, S.; Dillon, I.; Mehta, K.D. Phorbol ester promotes histone H3-Ser10 phosphorylation at the LDL receptor promoter in a protein kinase C-dependent manner. J. Lipid Res., 2004, 45(8), 1519-1527.
245. Cathcart, M.K.; McNally, A.K.; Morel, D.W.; Chisolm, G.M. 3rd, Superoxide anion participation in human monocyte-mediated oxidation of low-density lipoprotein and conversion of low-density lipoprotein to a cytotoxin. J. Immunol., 1989, 142(6), 1963-1969.
246. Li, Q.; Cathcart, M.K. Protein kinase C activity is required for lipid oxidation of low density lipoprotein by activated human monocytes. J. Biol. Chem., 1994, 269(26), 17508-17515.
247. Fleming, I.; Fisslthaler, B.; Dimmeler, S.; Kemp, B.E.; Busse, R. Phosphorylation of Thr(495) regulates Ca(2+)/calmodulindependent endothelial nitric oxide synthase activity. Circ. Res., 2001, 88(11), E68-75.
248. Fleming, I.; Mohamed, A.; Galle, J.; Turchanowa, L.; Brandes, R.P.; Fisslthaler, B.; Busse, R. Oxidized low-density lipoprotein increases superoxide production by endothelial nitric oxide synthase by inhibiting PKCalpha. Cardiovasc. Res., 2005, 65(4), 897-906.
249. DiCorleto, P.E.; de la Motte, C.A. Thrombin causes increased monocytic-cell adhesion to endothelial cells through a protein kinase C-dependent pathway. Biochem. J., 1989, 264(1), 71-77.
250. Weber, C.; Erl, W.; Weber, P.C. Enhancement of monocyte adhesion to endothelial cells by oxidatively modified low-density lipoprotein is mediated by activation of CD11b. Biochem. Biophys. Res. Commun., 1995, 206(2), 621-628.
251. Gong, N.; Wei, H.; Chowdhury, S.H.; Chatterjee, S. Lactosylceramide recruits PKCalpha/epsilon and phospholipase A2 to stimulate PECAM-1 expression in human monocytes and adhesion to endothelial cells. Proc. Natl. Acad. Sci. USA, 2004, 101(17), 6490-6495.
252. Kawakami, A.; Aikawa, M.; Alcaide, P.; Luscinskas, F.W.; Libby, P.; Sacks, F.M. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation, 2006, 114(7), 681-687.
253. Ma, H.T.; Lin, W.W.; Zhao, B.; Wu, W.T.; Huang, W.; Li, Y.; Jones, N.L.; Kruth, H.S. Protein kinase C beta and delta isoenzymes mediate cholesterol accumulation in PMA-activated macrophages. Biochem. Biophys. Res. Commun., 2006, 349(1), 214-220.
254. Venugopal, S.K.; Devaraj, S.; Yang, T.; Jialal, I. Alpha-tocopherol decreases superoxide anion release in human monocytes under hyperglycemic conditions via inhibition of protein kinase C-alpha. Diabetes, 2002, 51(10), 3049-3054.
255. Jialal, I.; Devaraj, S.; Kaul, N. The effect of alpha-tocopherol on monocyte proatherogenic activity. J. Nutr., 2001, 131(2), 389S-394S.
256. Leitges, M.; Mayr, M.; Braun, U.; Mayr, U.; Li, C.; Pfister, G.; Ghaffari-Tabrizi, N.; Baier,G.; Hu, Y.; Xu, Q. Exacerbated vein graft arteriosclerosis in protein kinase Cdelta-null mice. J. Clin. Invest., 2001, 108(10), 1505-1512.
257. Giardina, J.B.; Tanner, D.J.; Khalil, R.A. Oxidized-LDL enhances coronary vasoconstriction by increasing the activity of protein kinase C isoforms alpha and epsilon. Hypertension, 2001, 37(2 Part 2), 561-568.
258. Goerke, A.; Sakai, N.; Gutjahr, E.; Schlapkohl, W.A.; Mushinski, J.F.; Haller, H.; Kolch, W.; Saito, N.; Mischak, H. Induction of apoptosis by protein kinase C delta is independent of its kinase activity. J. Biol. Chem., 2002, 277(35), 32054-32062.
259. Li, D.; Liu, L.; Chen, H.; Sawamura, T.; Ranganathan, S.; Mehta, J.L. LOX-1 mediates oxidized low-density lipoproteininduced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation, 2003, 107(4), 612-617.
260. Mountain, D.J.; Singh, M.; Menon, B.; Singh, K. Interleukin-1beta increases expression and activity of matrix metalloproteinase-2 in cardiac microvascular endothelial cells: role of PKCalpha/beta1 and MAPKs. Am. J. Physiol. Cell. Physiol., 2007, 292(2), C867-875.
261. Hussain, S.; Assender, J.W.; Bond, M.; Wong, L.F.; Murphy, D.; Newby, A.C. Activation of protein kinase Czeta is essential for cytokine-induced metalloproteinase-1, -3, and -9 secretion from rabbit smooth muscle cells and inhibits proliferation. J. Biol. Chem., 2002, 277(30), 27345-27352.
262. Przyklenk, K.; Sussman, M.A.; Simkhovich, B.Z.; Kloner, R.A. Does ischemic preconditioning trigger translocation of protein kinase C in the canine model? Circulation, 1995, 92(6), 1546-1557.
263. Mitchell, M.B.; Meng, X.; Ao, L.; Brown, J.M.; Harken, A.H.; Banerjee, A. Preconditioning of isolated rat heart is mediated by protein kinase C. Circ. Res., 1995, 76(1), 73-81.
264. Sivaraman, V.; Hausenloy, D.J.; Kolvekar, S.; Hayward, M.; Yap, J.; Lawrence, D.; Di Salvo, C.; Yellon, D.M. The divergent roles of protein kinase C epsilon and delta in simulated ischaemiareperfusion injury in human myocardium. J. Mol. Cell. Cardiol., 2009, 46(5), 758-764.
265. Budas, G.R.; Disatnik, M.H.; Chen, C.H.; Mochly-Rosen, D. Activation of aldehyde dehydrogenase 2 (ALDH2) confers cardioprotection in protein kinase C epsilon (PKCvarepsilon) knockout mice. J. Mol. Cell. Cardiol., 48(4), 757-764.
266. Di-Capua, N.; Sperling, O.; Zoref-Shani, E. Protein kinase Cepsilon is involved in the adenosine-activated signal transduction pathway conferring protection against ischemia-reperfusion injury in primary rat neuronal cultures. J. Neurochem., 2003, 84(2), 409-412.
267. Kawamura, S.; Yoshida, K.; Miura, T.; Mizukami, Y.; Matsuzaki, M. Ischemic preconditioning translocates PKC-delta and -epsilon, which mediate functional protection in isolated rat heart. Am. J. Physiol., 1998, 275(2), H2266-2271.
268. Saito, N.; Shirai, Y. Protein kinase C gamma (PKC gamma): function of neuron specific isotype. J. Biochem., 2002, 132(5), 683-687.
269. Harada, K.; Maekawa, T.; Abu Shama, K.M.; Yamashima, T.; Yoshida, K. Translocation and down-regulation of protein kinase C-alpha, -beta, and -gamma isoforms during ischemia-reperfusion in rat brain. J. Neurochem., 1999, 72(6), 2556-2564.
270. Suen, P.C.; Wu, K.; Xu, J.L.; Lin, S.Y.; Levine, E.S.; Black, I.B. NMDA receptor subunits in the postsynaptic density of rat brain: expression and phosphorylation by endogenous protein kinases. Brain Res. Mol. Brain Res., 1998, 59(2), 215-228.
271. Saluja, I.; O'Regan, M.H.; Song, D.; Phillis, J.W. Activation of cPLA2, PKC, and ERKs in the rat cerebral cortex during ischemia/reperfusion. Neurochem. Res., 1999, 24(5), 669-677.
272. Miettinen, S.; Roivainen, R.; Keinanen, R.; Hokfelt, T.; Koistinaho, J. Specific induction of protein kinase C delta subspecies after transient middle cerebral artery occlusion in the rat brain: inhibition by MK-801. J. Neurosci., 1996, 16(19), 6236-6245.
273. Budas, G.R.; Churchill, E.N.; Mochly-Rosen, D. Cardioprotective mechanisms of PKC isozyme-selective activators and inhibitors in the treatment of ischemia-reperfusion injury. Pharmacol. Res., 2007, 55(6), 523-536.